Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications

被引:393
作者
Francque, Sven M. [1 ,2 ]
van der Graaff, Denise [1 ]
Kwanten, Wilhelmus J. [1 ,2 ]
机构
[1] Univ Antwerp, LEMP, Gastroenterol & Hepatol, Antwerp, Belgium
[2] Univ Antwerp Hosp, Dept Gastroenterol & Hepatol, Wilrijk Str 10, B-2650 Antwerp, Belgium
关键词
NAFLD; Cardiovascular disease; Pathophysiology; Clinical implications; SERUM HOMOCYSTEINE LEVELS; GROWTH-FACTOR; 21; WHOLE-BLOOD VISCOSITY; PLASMA FETUIN-A; ENDOTHELIAL DYSFUNCTION; INSULIN-RESISTANCE; MYOCARDIAL-INFARCTION; FIBROSIS PROGRESSION; STEATOHEPATITIS NASH; ARTERIAL STIFFNESS;
D O I
10.1016/j.jhep.2016.04.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent chronic liver diseases in the Western society and its prevalence is likely to rise even further. An increasing body of evidence shows that NAFLD is not only a potentially progressive liver disease, but also has systemic consequences. More specifically, evidence points out that NAFLD has to be considered as a significant independent risk factor for subclinical and clinical cardiovascular disease (CVD). Long-term follow-up studies demonstrate cardiovascular mortality to be the most important cause of death in NAFLD patients. Moreover, ample evidence associates NAFLD with endothelial dysfunction, increased pulse wave velocity, increased coronary arterial calcifications and increased carotid intima media thickness, all established markers for CVD. Despite of all this evidence, the mechanisms by which NAFLD causally contributes to CVD are not fully elucidated. Furthermore, an extensive overview of all potential pathophysiological mechanisms and the corresponding current data are lacking. In this review we summarise current knowledge, originating from fundamental and clinical research, that mechanistically links NAFLD to CVD. Subsequently, the impact of CVD on current clinical practice and future research in the area of NALFD are discussed. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:425 / 443
页数:19
相关论文
共 50 条
[41]   Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease [J].
Pisetta, Chiara ;
Chille, Claudia ;
Pelizzari, Giovanni ;
Pigozzi, Marie Graciella ;
Salvetti, Massimo ;
Paini, Anna ;
Muiesan, Maria Lorenza ;
De Ciuceis, Carolina ;
Ricci, Chiara ;
Rizzoni, Damiano .
HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2020, 27 (04) :321-330
[42]   Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease [J].
Simon, Tracey G. ;
Roelstraete, Bjorn ;
Alkhouri, Naim ;
Hagstrom, Hannes ;
Sundstrom, Johan ;
Ludvigsson, Jonas F. .
GUT, 2023, 72 (03) :573-580
[43]   Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease [J].
Janssen, Arne ;
Grobbee, Diederick E. ;
Dendale, Paul .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (10) :1059-1063
[44]   Non-alcoholic fatty liver disease is not independent risk factor for cardiovascular disease event: A cohort study [J].
Motamed, Nima ;
Ajdarkosh, Hossein ;
Ahmadi, Maral ;
Perumal, Dhayaneethie ;
Ashrafi, G. Hossein ;
Nikkhah, Mehdi ;
Faraji, Amir Hossein ;
Maadi, Mansooreh ;
Khoonsari, Mahmoodreza ;
Rezaie, Nader ;
Farahani, Behzad ;
Tameshkel, Fahimeh Safarnezhad ;
Ameli, Mitra ;
Panahi, Mahshid ;
Niya, Mohammad Hadi Karbalaie ;
Zamani, Farhad .
WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (06) :323-331
[45]   Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications [J].
Byrne, Christopher D. ;
Targher, Giovanni .
DIABETES OBESITY & METABOLISM, 2022, 24 :28-43
[46]   Increased Risk for Cardiovascular Events in Patients with Diabetic Kidney Disease and Non-Alcoholic Fatty Liver Disease [J].
Chinnadurai, Rajkumar ;
Chrysochou, Constantina ;
Kalra, Philip A. .
NEPHRON, 2019, 141 (01) :24-30
[47]   Non-Alcoholic Fatty Liver Disease and HIV/AIDS: A New Way of Modulation of Cardiovascular Risk [J].
Ahmed, Mohamed H. ;
Husain, Nazik Elmalaika ;
Malik, Akif ;
Woodward, Clare ;
Mital, Dushyant .
AIDS REVIEWS, 2017, 19 (04) :190-197
[48]   Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population [J].
Pennisi, Grazia ;
Di Marco, Vito ;
Buscemi, Carola ;
Mazzola, Giovanni ;
Randazzo, Cristiana ;
Spatola, Federica ;
Craxi, Antonio ;
Buscemi, Silvio ;
Petta, Salvatore .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (09) :2389-2396
[49]   Pharmacological Treatment for Non-alcoholic Fatty Liver Disease [J].
Francque, Sven ;
Vonghia, Luisa .
ADVANCES IN THERAPY, 2019, 36 (05) :1052-1074
[50]   Non-Alcoholic Fatty Liver Disease and Aterial Stiffness [J].
Mariano, Duarte ;
Gonzalez, Ballerga Esteban ;
Jorge, Daruich ;
Vazquez, Blanco Manuel ;
Juan, Sorda A. .
JOURNAL OF CLINICAL HYPERTENSION, 2013, 15